Hanall Biopharma (009420) — Cash Flow Quality Index
Hanall Biopharma (009420) has a Cash Flow Quality Index of 24.56x as of September 2025. Operating cash flow of ₩7.34 Billion exceeds net income of ₩298.96 Million, indicating high earnings quality where cash backs reported profits. Explore 009420 long-term investments to assets to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Hanall Biopharma Cash Flow Quality Index (2016–2023)
Historical Cash Flow Quality Index for Hanall Biopharma across 8 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 009420 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Hanall Biopharma (2016–2023)
Year-by-year earnings quality comparison for Hanall Biopharma. For live market cap and the full company financial profile, see Hanall Biopharma market cap and net worth.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2023 | 8.45x | ₩29.64 Billion | ₩3.51 Billion | ▼ -33.3% |
| 2022 | 12.68x | ₩25.20 Billion | ₩1.99 Billion | ▲ +14992.1% |
| 2021 | 0.08x | ₩839.87 Million | ₩10.00 Billion | ▲ +97.7% |
| 2020 | 0.04x | ₩929.29 Million | ₩21.87 Billion | ▼ -96.0% |
| 2019 | 1.07x | ₩20.49 Billion | ₩19.17 Billion | ▲ +217.8% |
| 2018 | -0.91x | ₩-2.99 Billion | ₩3.30 Billion | ▼ -112.5% |
| 2017 | 7.25x | ₩42.14 Billion | ₩5.81 Billion | ▲ +271.8% |
| 2016 | 1.95x | ₩3.95 Billion | ₩2.03 Billion | — |